Table 1 Basic characteristics of enrolled studies
From: Application of nano-hydroxyapatite matrix graft in inter-vertebral fusion therapy: a meta-analysis
Author/year | Country | Study design | Age (years) | Sample Size nHA/noHA(n) | Type of surgery | Outcome indicators | Follow-up time (months) | NOS score |
|---|---|---|---|---|---|---|---|---|
D.Neen 2006 [16] | UK | PCCT | 49/48 | 50/50 | PLIF | ①,⑨ | 24 | 7 |
E.Dawson 2009 [19] | USA | PCCT | 55.9/56.9 | 25/21 | PLDIF | ①,⑤,⑥,⑦,⑨ | 24 | 8 |
X.H.Liu 2012 [30] | China | PCCT | 51.4/52.4 | 31/26 | ACDF | ①,②,③,④,⑥,⑨ | 24 | 7 |
J.X.Liang 2018 [29] | China | PCCT | 50.5/52.5 | 124/50 | ACDF | ①,②,③,④,⑤,⑥,⑦,⑧ | 52 | 8 |
C.Zhu 2021 [26] | China | PCCT | 54.5/55.3 | 32/32 | TLIF | ①,③,④,⑤,⑥,⑧ | 47 | 7 |
T.Yoshii 2021 [25] | Japan | PCCT | 70.2/73.8 | 46/46 | PLIF | ①,⑨ | 24 | 8 |
J.Delecrin 2000 [32] | France | RCT | 18.2/17.5 | 28/30 | PLIF | ④,⑤,⑥,⑨ | 24 | 8 |
J.R.McConnell 2003 [33] | UK | RCT | 47/47 | 13/16 | ACDF | ①,②,⑨ | 24 | 8 |
P.Korovessis 2005 [27] | Greece | RCT | 58/61 | 20/19 | PLDIF | ⑤,⑥,⑦,⑧ | 48 | 8 |
J.R.Dimar 2009 [14] | USA | RCT | 53.2/52.3 | 239/224 | PLDIF | ①,⑤,⑥,⑨ | 24 | 7 |
N.H.vonderHoeh 2017 [22] | Germany | RCT | 64.3/65.6 | 24/24 | TLIF | ①,⑦,⑧,⑨ | 12 | 8 |
J.H.Cho 2017 [21] | Korea | RCT | 64.9/62 | 42/51 | PLDIF | ①,⑦,⑧,⑨ | 6 | 8 |
M.Rickert 2019 [23] | Germany | RCT | 60.6/66.1 | 20/20 | ALIF | ①,⑧,⑨ | 12 | 8 |
W.Chen 2020 [28] | China | RCT | 48.6/48 | 19/10 | TLIF | ①,③,④,⑤,⑥,⑦,⑨ | 36 | 7 |
B.L.Ma 2016 [31] | China | RCT | 49.2/48 | 20/10 | TLIF | ①,④,⑤,⑥,⑦,⑨ | 12 | 7 |
W.C.Chang 2009 [18] | China | RPCT | 58.5/51.39 | 22/23 | ACDF | ①,⑨ | 6 | 7 |
Q.x.Deng 2016 [20] | China | RPCT | 53.2/53.6 | 124/142 | TLIF | ①,②,③,④,⑤,⑥,⑧,⑨ | 47 | 8 |
B. Hu 2019 [4] | China | RPCT | 52.5/51.3 | 47/51 | ACDF | ①,②,③,④,⑤,⑥,⑧,⑨ | 84 | 7 |
Tayfun Cakir 2021 [24] | Turkey | RPCT | 61.4/66.1 | 54/51 | PLIF | ③,⑦,⑧,⑨ | 60 | 8 |